Whipplewood Advisors LLC Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)

Whipplewood Advisors LLC purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 4,037 shares of the company’s stock, valued at approximately $159,000.

Several other institutional investors have also recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB acquired a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Darwin Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $43,000. Highline Wealth Partners LLC acquired a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $39,000. Western Pacific Wealth Management LP increased its holdings in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after acquiring an additional 500 shares during the last quarter. Finally, Spire Wealth Management increased its holdings in shares of CRISPR Therapeutics by 303.7% during the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock worth $78,000 after acquiring an additional 1,482 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. This represents a 7.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Stock Down 1.8 %

Shares of CRSP stock opened at $43.62 on Friday. CRISPR Therapeutics AG has a twelve month low of $36.52 and a twelve month high of $90.62. The company has a market cap of $3.74 billion, a P/E ratio of -9.98 and a beta of 1.67. The business has a fifty day simple moving average of $42.36 and a 200 day simple moving average of $45.99.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

CRSP has been the topic of a number of recent analyst reports. Barclays boosted their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Citigroup decreased their target price on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a report on Tuesday, February 18th. HC Wainwright restated a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Stifel Nicolaus reduced their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Finally, The Goldman Sachs Group reduced their price target on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $74.40.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.